CC BY-NC-ND 4.0 · International Journal of Epilepsy 2016; 03(02): 095-097
DOI: 10.1016/j.ijep.2016.10.002
Case report
Thieme Medical and Scientific Publishers Private Ltd.

Macular cherry red spot is an important diagnostic marker in children with myoclonic epilepsies

Minal V. Kekatpure
a   Division of Pediatric Neurology, Department of Neurology, Amrita Institute of Medical Sciences, Kochi, Kerala, India
,
K. P. Vinayan
a   Division of Pediatric Neurology, Department of Neurology, Amrita Institute of Medical Sciences, Kochi, Kerala, India
,
Sheela Nampoothiri
b   Department of Genetics, Amrita Institute of Medical Sciences, Kochi, Kerala, India
,
Gopal Pillai
c   Department of Ophthalmology, Amrita Institute of Medical Sciences, Kochi, Kerala, India
,
Anand Kumar
d   Department of Neurology, Amrita Institute of Medical Sciences, Kochi, Kerala, India
› Author Affiliations
Further Information

Publication History

Received: 17 July 2016

Accepted: 04 October 2016

Publication Date:
06 May 2018 (online)

Abstract

Symptomatic myoclonus is the major presenting feature of a small but very important and genetically diverse group of rare disorders included under the umbrella of progressive myoclonus epilepsy (PME) and progressive myoclonus ataxia (PMA) syndromes. These disorders often require extensive investigations to arrive at an accurate diagnosis. We present a case series highlighting the importance of a detailed fundoscopic eye examination; particularly when occurring in conjunction with a clinical history of myoclonus, developmental regression and other systemic features in clinching an etiologic diagnosis of storage disorder, specifically, gangliosidosis and sialidosis in children with suspected progressive myoclonus epilepsies. The causes of macular cherry red spot (CRS) on fundoscopic examination are limited and in a given child may provide an important clue for narrowing the differential diagnoses and finally making an accurate diagnosis. Current literature on symptomatic myoclonus, cherry red spot and their occurrence in PME/PMA syndromes is also reviewed.

1 Current address: Department of Pediatric Neurology, Mazumdar Shaw Medical Center, Narayana Health City, Bengaluru 560099, Karnataka, India.


 
  • References

  • 1 Marsden CD, Hallett M, Fahn S. The nosology and pathophysiology of myoclonus. Marsden CD, Fahn S. Movement Disorders. 1982. Butterworths; London: 196-248
  • 2 Caviness JN, Alving LI, Maraganore DM, Black RA, McDonnell SK, Rocca WA. The incidence and prevalence of myoclonus in Olmsted County, Minnesota. Mayo Clin Proc 74 (06) 1999; 565-569
  • 3 Marsden CD, Harding AE, Obeso JA, Lu CS. Progressive myoclonic ataxia (the Ramsay Hunt syndrome). Arch Neurol 47 1990; 1121-1125
  • 4 Borg M. Symptomatic myoclonus. Neurophysiol Clin 36 2006; 309-318
  • 5 Taylor D. Neurometabolic diseases. Taylor D. Pediatric Opthalmology. 2nd ed.. 1997. Blackwell Science; Boston, MA: 772-793
  • 6 Wirrell E. Infantile, childhood, and adolescent epilepsies. Continuum 22 2016; 60-93
  • 7 Satishchandra P, Sinha S. Progressive myoclonic epilepsy. Neurol India 58 2010; 514-522
  • 8 Gravel RA, Kaback MM, Proia RL, Sandhoff K, Suzuki K, Suzuki K. The GM2 gangliosidoses. Scriver CR, Beaudet AR, Sly W, Valle D. The Metabolic and Molecular Bases of Inherited Diseases. 8th ed.. 2001. McGraw-Hill; New York: 3827-3876
  • 9 Kivlin JD, Sanborn GE, Myers GG. The cherry red spot in Tay-Sachs and other storage disorders. Ann Neurol 17 1985; 356-360
  • 10 Ospina LH, Lyons CJ, McCormick AQ. Cherry red spot or “Perifoveal white patch?”. Can J Opthalmol 40 2005; 609-610